Related Experiment Video
Updated: Feb 22, 2026
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Cost Utility Analysis of Fluticasone Exhalation Delivery System Versus Budesonide Nasal Irrigation for Chronic
Daniel Xiao1,2, Martin J Citardi1,2, William C Yao1,2
1Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School of The University of Texas Health Science Center at Houston, Houston, Texas, USA.
Background:
Chronic rhinosinusitis with nasal polyps (CRSwNP) is managed after sinus surgery with topical corticosteroids. Given limited distribution of nasal steroid sprays, patients have the option of either steroid nasal irrigation (SNI) or exhalation delivery system with fluticasone (EDS-FLU). This study evaluates the cost-effectiveness of EDS-FLU compared to SNI for CRSwNP.
Methods:
A cohort-style Markov decision-tree economic model with a 33-year time horizon was developed in TreeAgePro. Because EDS-FLU is not currently covered by Medicare, costs of medications were estimated using retail pricing. A willingness-to-pay threshold of $50,000/quality adjusted life year (QALY) was used to determine cost-effectiveness. One-way and probabilistic sensitivity analysis was conducted using 10,000 Monte Carlo simulations.
Results:
EDS-FLU had an incremental benefit of 0.41 QALYs compared to SNI. In base case analysis, EDS-FLU costs $140,966.63 after the study period, whereas SNI costs $40,817.50. With an ICER of $244,185.37/QALY, SNI is the more cost-effective strategy. Probabilistic sensitivity analysis reported SNI as the cost-effective strategy in 98.50% of simulations.
Conclusions:
Compared to EDS-FLU, SNI is the cost-effective strategy for treating CRSwNP following FESS. Changes in drug pricing and improvements in patient selection may cause adjustments in the most cost-effective strategy for CRSwNP management.
More Related Videos
Related Concept Videos
01:23Inhaled Medications
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:16Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
01:22Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
01:26COPD: Management Using Bronchodilators and Corticosteroids